{
    "clinical_study": {
        "@rank": "90548", 
        "acronym": "REIN-PD", 
        "arm_group": {
            "arm_group_label": "Levodopa/Carbidopa(200mg/50mg)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved\n      and neuropsychiatric traits related to ICD are changed or not when switching dopamine\n      agonist to levodopa/carbidopa in patients with Parkinson's disease who have been treated\n      with dopaminergic medications."
        }, 
        "brief_title": "Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Impulse Control Disorder", 
        "condition_browse": {
            "mesh_term": "Impulse Control Disorders"
        }, 
        "detailed_description": {
            "textblock": "-  PRIMARY OBJECTIVE To evaluate the improvement of mMIDI(modified version of Minnesota\n           Impulsive Disorders Interview,Korean version) score from the baseline to 12 weeks or\n           LOCF(Last Observation Carried Forward)\n\n        -  SECONDARY OBJECTIVE i) To evaluate the improvement of neuropsychiatric profiles from\n           the baseline to 12 weeks or LOCF ii) To evaluate the improvement of UPDRS(Unified\n           Parkinson's Disease Rating Scale)Score from the baseline to 12 weeks or LOCF"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with a diagnosis of idiopathic PD according to United Kingdom Parkinson's\n             Disease Brain Bank Criteria\n\n          -  mMIDI \u2265 3 score with ICD\n\n          -  Patients must be on an anti-parkinson treatment at least 6 months before screening.\n\n          -  for this protocol, dopamine agonists should be included in his/her anti-parkinson\n             treatment.\n\n          -  30years \u2264 patients < 80years of age, male or female\n\n          -  patients must give written informed consent before any assessment is performed\n\n        Exclusion Criteria:\n\n          -  Requirement of treatment with serious cognitive disorder, behavioral disorder, or\n             mental illness currently or in the future\n\n          -  for the patients \u2264 65years: K-MMSE(korean version of Mini-Mental State Exam) \u226424, or\n             for the patients \u2265 66years: K-MMSE \u2264 20, or the patients have dementia(incl. early\n             dementia) even though K-MMSE score is more than 20\n\n          -  Requirement of treatment more than 6times per day due to the severe motor\n             fluctuation.\n\n          -  Severe dyskinesia\n\n          -  DBS(Deep Brain Stimulation)or any other surgical treatment\n\n          -  History of melanoma or not-diagnostic skin trouble/skin lesions\n\n          -  narrow angle glaucoma\n\n          -  clinically serious surgical or medical condition\n\n          -  malignant tumor\n\n          -  use of other investigational drugs at the time of enrollment within 4weeks\n\n          -  pregnant, nursing or lactating women\n\n          -  women of child-bearing potential\n\n          -  history of hypersensitivity or allergy to levodopa/carbidopa\n\n          -  any serious disease accordidng to the investigator's discretion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01683253", 
            "org_study_id": "SKL004"
        }, 
        "intervention": {
            "arm_group_label": "Levodopa/Carbidopa(200mg/50mg)", 
            "intervention_name": "Levodopa/Carbidopa(200mg/50mg)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carbidopa", 
                "Levodopa", 
                "Dopamine", 
                "Dopamine Agonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 10, 2012", 
        "number_of_arms": "1", 
        "official_title": "The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy", 
        "overall_contact": {
            "last_name": "kim", 
            "phone": "+82 2 768 9422"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Jinwhan Cho, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the improvement of mMIDI(Korean version) score from the baseline to 12 weeks or LOCF(Last Observation Carried Forward)", 
            "measure": "mMIDI(modified Minnesota Impulsive Disorders Interview)", 
            "safety_issue": "No", 
            "time_frame": "12weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01683253"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the improvement of neuropsychiatric profiles from the baseline to 12 weeks or LOCF\n* Neuropsychological assessment\nGeneral cognitive status: K-Minimental status exam(K-MMSE)\nPsychiatric profile:\nNeuropsychiatric inventory (K-NPI)\nBeck depression inventory (BDI)\nBarratt impulsiveness scale (BIS)\nBeck anxiety inventory (BAI)\nState-trait anger expression inventory (STAXI)\nObsessive compulsive inventory (OCI)\nEvaluation of global change:\nPatient global impression of improvement (PGI-I)\nClinical global impression of improvement (CGI-I)", 
            "measure": "Neuropsychiatric profile", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Sandoz Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}